{
  "paper_metadata": {
    "pmid": "39438716",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on the BRCA2 variant c.517-2A>G, including clinical significance, penetrance data, and individual records."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.517-2A>G",
      "protein_notation": null,
      "genomic_position": "rs81002858",
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 11,
        "demographics": "60% female, mean age at recruitment 49.8 years (range 18\u201393)",
        "phenotype": "breast and ovarian cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 9,
        "affected_count": 5,
        "unaffected_count": 4,
        "uncertain_count": null,
        "penetrance_percentage": 55.56,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 52,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "One of the female c.517-2A>G carrier participants has a diagnosis of breast cancer."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": 52,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "ovarian cancer",
          "evidence_sentence": "One of ovarian cancer."
        },
        {
          "individual_id": "P3",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": null,
          "evidence_sentence": "None of the other seven carriers (four females and three males) had any cancer code recorded."
        },
        {
          "individual_id": "P4",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": null,
          "evidence_sentence": "None of the other seven carriers (four females and three males) had any cancer code recorded."
        },
        {
          "individual_id": "P5",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": null,
          "evidence_sentence": "None of the other seven carriers (four females and three males) had any cancer code recorded."
        },
        {
          "individual_id": "P6",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": null,
          "evidence_sentence": "None of the other seven carriers (four females and three males) had any cancer code recorded."
        },
        {
          "individual_id": "P7",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": null,
          "evidence_sentence": "None of the other seven carriers (four females and three males) had any cancer code recorded."
        },
        {
          "individual_id": "P8",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": null,
          "evidence_sentence": "None of the other seven carriers (four females and three males) had any cancer code recorded."
        },
        {
          "individual_id": "P9",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": null,
          "evidence_sentence": "None of the other seven carriers (four females and three males) had any cancer code recorded."
        }
      ],
      "functional_data": {
        "summary": "The c.517-2A>G variant is predicted to affect mRNA splicing, resulting in a significantly altered protein due to exon skipping.",
        "assays": [
          "Sanger sequencing",
          "multifactorial likelihood quantitative analysis"
        ]
      },
      "segregation_data": "The variant segregates with female breast and ovarian cancer in diagnosed cases.",
      "population_frequency": "Carrier frequency 0.4% in VIKING I; ~130-fold higher than in UK Biobank.",
      "evidence_level": "Strong evidence based on multifactorial likelihood analysis (posterior probability 0.9994).",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The variant is part of a founder effect in the Shetland population.",
      "key_quotes": [
        "The c.517-2A>G variant (also known as IVS6-2A>G) has been reported in multiple individuals affected with Hereditary Breast and Ovarian Cancer worldwide, and is classed as pathogenic.",
        "The interpretation that this base substitution is a pathogenic variant was demonstrated independently by multifactorial likelihood quantitative analysis (definitely pathogenic, posterior probability 0.9994)."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data was extracted from the main text."
  }
}